The Obesity-Inflammation Axis: How Incretin-Immunotherapy Combinations Are Reshaping Autoimmune Disease Treatment
核心洞察
Obesity (搜索) drives chronic low-grade inflammation through dysfunctional adipose tissue, releasing pro-inflammatory adipokines and cytokines that amplify immune dysregulation across multiple autoimmune diseases.
Clinical trials combining GLP-1 (搜索)/GIP (搜索) receptor agonists with immunotherapies show significantly superior outcomes, with the TOGETHER PsA trial demonstrating 31.7% ACR50 response for combination therapy versus 0.8% for monotherapy.
Obesity (搜索) modifies treatment response in a mechanism-of-action-specific manner, with TNF and IL-17 (搜索) inhibitors showing reduced efficacy in obese patients while JAK inhibitors remain BMI-independent.
The convergence of obesity (搜索) and immunology is emerging as one of the most promising frontiers in pharmaceutical innovation, as mounting evidence reveals that targeting the obesity-inflammation axis can dramatically amplify the effectiveness of immunotherapies across a spectrum of autoimmune diseases. Recent clinical trial data, particularly from Lilly's TOGETHER program, demonstrate that combining incretin-based weight-loss therapies with biologic immunotherapies produces outcomes far superior to immunotherapy alone—challenging the traditional siloed approach to managing immune disorders in patients with obesity.
The biological underpinnings of obesity (搜索)-driven inflammation
White adipose tissue, long understood as a passive energy reservoir, is now recognized as an active endocrine organ that fundamentally shapes immune function. In obesity (搜索), dysfunctional white adipose tissue triggers the release of pro-inflammatory adipokines—including leptin, resistin, and visfatin—alongside pro-inflammatory cytokines such as TNF-α (搜索), IL-6, IL-1β, monocyte chemoattractant protein-1 (MCP-1), and plasminogen activator inhibitor-1 (PAI-1).
Leptin, in particular, stimulates the inflammatory phenotype of T-cells and macrophages, encourages Th17 lymphocyte differentiation and production of the pro-inflammatory cytokine IL-17 (搜索), while simultaneously suppressing anti-inflammatory regulatory T-cells (Tregs). Concurrently, obesity (搜索) decreases levels of the anti-inflammatory adipokine adiponectin, further tilting the immune balance toward a chronic, low-grade inflammatory state.
This interplay between adipose-derived inflammation and immune dysregulation elevates obesity (搜索) from a mere risk factor to an active disease modifier across multiple autoimmune conditions, including psoriatic disease, rheumatoid arthritis (搜索), inflammatory bowel disease (搜索), and asthma (搜索).
Clinical evidence: the TOGETHER trials
The most compelling evidence for targeting the obesity (搜索)-inflammation axis comes from Lilly's TOGETHER clinical trial program. In the TOGETHER PsA trial, at 36 weeks, 31.7% of obese psoriatic arthritis (搜索) patients receiving Taltz (ixekizumab, an IL-17 (搜索) inhibitor) plus Zepbound (tirzepatide, a GLP-1 (搜索)/GIP (搜索) receptor agonist) achieved ACR50 response with at least 10% weight loss, compared to just 0.8% for Taltz monotherapy. On a secondary endpoint, the combination delivered 33.4% ACR50 response versus 20.4% for Taltz alone.
Similarly, in the TOGETHER PsO trial, at 36 weeks, 27.1% of obese psoriasis (搜索) patients treated with the Taltz-Zepbound combination achieved PASI 100 with at least 10% weight loss, versus 5.8% for Taltz alone. The combination achieved 40.6% PASI 100 on secondary endpoints compared to 29% for monotherapy.
Notably, ACR50 response in the PsA trial was already observed at week 4—before any significant weight loss had occurred—suggesting that early patient benefits stem from direct anti-inflammatory and immunomodulatory effects of Zepbound on key disease pathways, including invariant natural killer T-cells, lymphocyte migration, and pro-inflammatory cytokines, with weight-loss-related benefits realized later.
Disease-specific impacts of obesity (搜索) on immune disorders
The impact of obesity (搜索) on treatment response varies by mechanism of action and disease. In psoriatic disease, TNF and IL-17 (搜索) inhibitors show lower response rates in obese patients, while IL-23 (搜索) and PDE4 inhibitors appear minimally affected. Obesity reduces the likelihood of achieving remission with TNF inhibitors in psoriatic arthritis (搜索) by approximately 50%.
In rheumatoid arthritis (搜索), a prospective observational study from the NORD-STAR registry found that obesity (搜索) was associated with a lower likelihood of good treatment response to both conventional anti-rheumatic drugs—including sulfasalazine, hydroxychloroquine, and glucocorticoids—and several biologics spanning different mechanisms, including Cimzia (TNF inhibitor), Orencia (CTLA-4 immunoglobulin), and Actemra (IL-6 inhibitor). Conversely, the efficacy of JAK inhibitors in RA patients was found to be independent of BMI, suggesting obesity does not interfere with the JAK-STAT pathway.
In inflammatory bowel disease (搜索), obesity (搜索) affects ulcerative colitis (搜索) and Crohn's disease (搜索) differently. High BMI appears to have a protective effect on Crohn's disease, with increased time to flares and reduced endoscopic recurrence, whereas poorer outcomes and increased hospitalization risk have been observed in ulcerative colitis. A meta-analysis found that obesity was associated with higher odds of anti-TNF treatment failure in UC patients for both fixed-dose and weight-based regimens, though it did not affect therapeutic success in Crohn's disease.
In asthma (搜索), obesity (搜索) is associated with increased frequency and severity of exacerbations, airway hyper-responsiveness, and decreased pulmonary function. Obese asthma patients exhibit lower prevalence of type 2 inflammation biomarkers—including sputum eosinophilia, blood eosinophilia, IgE, and exhaled nitric oxide—indicating a neutrophilic-driven inflammatory phenotype that is more refractory to conventional therapies, including corticosteroids.
Beyond weight loss: direct immunomodulatory effects of incretins
An intriguing observation from combination trials points to the monotherapy potential of incretins in immunology. Improvements in treated immune disorders can precede weight loss, suggesting direct anti-inflammatory effects. Psoriasis (搜索) patients receiving liraglutide experienced improvements in PASI, C-reactive protein, and quality of life independent of weight loss. Pre-clinical evidence suggests GLP-1 (搜索) directly modulates several dysregulated inflammatory pathways and immune cell lineages relevant to IBD pathogenesis and contributes to maintaining gut barrier integrity.
Lilly is now investigating the GLP-1 (搜索)/GIP (搜索) receptor agonist brenipatide (搜索) in a phase 2 trial for uncontrolled, moderate to severe asthma (搜索)—notably, BMI is not included in the eligibility criteria, indicating that the direct immunomodulatory effect, rather than weight loss potential, is the primary focus.
The emerging pipeline and strategic implications
Multiple ongoing clinical trials are investigating incretin-immunotherapy combinations across autoimmune diseases. These include the phase 4 TOGETHER-AMPLIFY-PsO and TOGETHER-AMPLIFY-PsA trials (Taltz plus Zepbound), the phase 3b COMMIT-CD and COMMIT-UC trials (Omvoh plus Zepbound), and a University of Miami-led phase 4 trial combining infliximab or adalimumab with Zepbound in Crohn's disease (搜索).
Future directions may include incretin/IL-6 combinations for rheumatoid arthritis (搜索), incretin/alarmin combinations for non-type 2 asthma (搜索), and incretin/NLRP3 combinations targeting both upstream metabolic inflammation and downstream inflammasome activity for difficult-to-treat indications such as neutrophilic COPD or complex IBD phenotypes.
However, significant challenges remain for integrated obesity (搜索)-immunology care, including the absence of weight loss from standard immunology guidelines, care fragmentation across prescriber specialties, payer concerns about additive costs, and the need for clear clinical guidance on patient selection and combination dosing. Early stakeholder engagement and compelling evidence demonstrating benefits against payer- and patient-relevant endpoints will be critical for market adoption.